Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Fondazione Italiana Linfomi - ETS
Ohio State University Comprehensive Cancer Center
Memorial Sloan Kettering Cancer Center
Mayo Clinic
Fox Chase Cancer Center
Ohio State University Comprehensive Cancer Center
Memorial Sloan Kettering Cancer Center
Celgene
Memorial Sloan Kettering Cancer Center
City of Hope Medical Center
Canadian Cancer Trials Group
The Lymphoma Academic Research Organisation
Columbia University
National Institutes of Health Clinical Center (CC)
Rhizen Pharmaceuticals SA
University of Birmingham
University of Virginia
Big Ten Cancer Research Consortium
Washington University School of Medicine
Columbia University
University of California, San Francisco
Yale University
Celgene
Celgene
Celgene
Celgene
Fondazione Italiana Linfomi - ETS
Northwestern University
Celgene
National Cancer Institute (NCI)
NYU Langone Health
Columbia University
M.D. Anderson Cancer Center
Takeda
National Institutes of Health Clinical Center (CC)
Mayo Clinic
National Cancer Institute (NCI)
The Lymphoma Academic Research Organisation
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)